👋 hey researchers,
Last month, FDA staff reviewed seven peptide families and recommended keeping all seven off the federal compounding list.
Then the advisory committee voted yes on six of them.
BPC-157, KPV, TB-500, MOTS-c, epitalon, and semax got favorable votes. Emideltide, better known as DSIP, did not. The first BPC-157 result drew applause inside FDA headquarters, which is unusual for a federal evidence meeting and very on-brand for the peptide world in 2026.
Today: what the committee actually decided, why the room split, and what happens next. Plus fresh retatrutide and eloralintide data, and a peptide seller heading to federal prison.
the room said yes. the rulebook has not moved yet.
On July 23 and 24, the Pharmacy Compounding Advisory Committee, or PCAC, considered whether seven peptide families should be eligible for the 503A Bulks List. That is the list of ingredients a state-licensed compounding pharmacy may use for an individual patient with a prescription, provided the pharmacy follows the rest of section 503A.
This was a vote about a possible compounding pathway. It was not a drug approval vote.
The scoreboard:
The split came down to two different ideas of what the committee was supposed to solve.
The yes bloc saw an access and harm-reduction question. People already buy these compounds online. Supporters argued that prescriptions, physician oversight, and licensed pharmacies could create a safer route than mystery vials from research-chemical sites. To them, the vote opened the door to regulated compounding. It did not certify that every claim was proven.
FDA staff and the no bloc saw an evidence question. Could a pharmacist reliably identify the substance? Could a compounder control impurities, aggregates, sterility, endotoxin, and stability? Was there enough human evidence to support a dose, route, use, and safety profile?
For most of the nominees, the answers were thin. "BPC-157" can mean a free base or acetate salt. "TB-500" is often used for both a short fragment and the much larger thymosin beta-4 protein. KPV and TB-500 had no human exposure data for the uses reviewed. MOTS-c leaned on cell and animal studies. Epitalon lacked clinical safety data for subcutaneous use. Semax had foreign clinical experience, especially from Russia, but FDA still found the evidence inadequate for the nominated neurological uses.
BPC-157 had the most familiar name, but FDA found only five small, short human studies with exploratory dosing and limited safety monitoring. The committee still passed it 8-6-1.
The voting pattern tells the story. For BPC-157, KPV, and TB-500, the eight yes votes came from the original bloc. All six temporary members seated for those topics voted no, and the NABP representative abstained. Three very different evidence files produced the same 8-6-1 result because the two groups were applying different thresholds.
Why did DSIP lose? Its insomnia studies were inconsistent, while the narcolepsy and opioid-withdrawal evidence came from tiny or uncontrolled reports. FDA found no effectiveness data for the proposed subcutaneous route. Intravenous studies also reported headache, nausea, vertigo, and progressive hypotension after a second injection. One access-friendly member switched to no because of the possible downstream harm.
In short: the six winners cleared the committee's access argument. They did not clear FDA's evidence standard. DSIP paired a weak file with a safety signal visible enough to break the coalition.
So what changes now? For patients, prescribers, compounders, and online vendors: nothing immediate. PCAC advises FDA. FDA can accept, narrow, or reject its recommendations. Adding a substance to the final 503A list normally requires a proposed rule, public comments, and a final rule. That can take months or years.
The votes are still meaningful. Six peptides now have the strongest federal access signal they have received, and current HHS leadership appears open to broader peptide compounding. But no peptide was approved, none joined the final list, and research-use-only sellers received no new permission to market products for humans.
retatrutide added two more Phase 3 wins.
Lilly's TRIUMPH-2 enrolled 1,152 adults with obesity or overweight and type 2 diabetes. At 80 weeks, the 12 mg group lost an average 20.8% of body weight, versus 4.0% on placebo. A1C fell by as much as 1.6 percentage points.
TRIUMPH-3 studied 1,949 adults with severe obesity and established cardiovascular disease. The 12 mg group lost 22.6%, versus 3.2% on placebo. The trial recorded too few major cardiovascular events to prove a heart benefit, and 13.5% of the top-dose group discontinued because of adverse events.
Lilly now has five positive Phase 3 studies and plans a US filing in Q1 2027. Retatrutide remains investigational. An online vial using the name is not Lilly's trial drug.
eloralintide found a second engine.
Eloralintide is Lilly's weekly amylin agonist. Its standalone Phase 2 trial showed up to 20.1% mean weight loss at 48 weeks. New early data paired it with tirzepatide and reported up to 29.0% at week 32.
Large number, small study. These were early dose-finding groups reported in a conference abstract, with the full presentation and mature safety data still ahead. The useful signal is the combination: tirzepatide brings GIP and GLP-1; eloralintide adds amylin. Now Lilly needs to show that the effect survives a much larger trial without stacking the side effects too.
Paradigm Peptides got the opposite kind of result.
Paradigm owner Matthew Kawa was sentenced on July 30 to five years and ten months in federal prison. Employee Jennifer Stechkober received one year and four months. They had pleaded guilty in December 2025 after selling peptides, hCG, and SARMs to thousands of customers. Investigators found that several products labeled as SARMs contained testosterone, a Schedule III controlled substance.
Small correction to the online chatter: July was the sentencing, not the arrest.
The PCAC vote and the Paradigm sentence landed six days apart. One explored a legal route through prescriptions and licensed pharmacies. The other showed that a friendlier advisory committee does not legalize the gray market.
your peptide research desk, now pocket-sized.
With the Reptides app, you can scan a vial to pull up its grade, run reconstitution math without rebuilding the equation in Notes, and keep a private research journal that syncs across devices.
The wiki and the journal stay free. So does tracking a stack, one COA check a day, your first vial scan, and ten Ask questions a month.
get Reptides on the App Store →
want the full research layer?
Membership unlocks every deep dive, the full research lab, supplier and outcome tools, stack grading, saved reconstitution context, unlimited COA checks, advanced journal tools, and unlimited Ask Reptides.
It also keeps Reptides independent: no vendor money, peptide-vendor affiliate links, or paid grades.
$100 once. Lifetime access covers the same account on web, desktop, and iOS, with no subscription or renewal.
reptides editorial · research reference, not medical advice.